CBM 23.46 Cambrex Corp $CBM Hit a 52 week high of 23.51 Closing the day 09:44 at 23.46 +0.10 +0.43% With a day low of 23.37 and a total volume of 10,333.
CBM Recent Posts: http://investorshangout.com/Cambrex-Corp-CBM-50451/
CBM Cambrex Corp Recent Headline News
Cambrex Shares Up 20.2% Since SmarTrend's Buy Recommendation (CBM)
Comtex SmarTrend(R) - Wed Nov 12, 9:19AM CST
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on October 28th, 2014 at $19.26. In approximately 2 weeks, Cambrex has returned 20.18% as of today's recent price of $23.14.
CBM: 23.28 (-0.08)
Can the Rally in Cambrex (CBM) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:34AM CST
Can the Rally in Cambrex (CBM) Shares Continue?
CBM: 23.28 (-0.08)
NYSE stocks posting largest percentage increases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
DHX: 11.25 (-0.06), HLF: 37.37 (-0.48), CBM: 23.28 (-0.08), ESI: 10.25 (+0.23), JMP: 7.51 (-0.04), THR: 25.45 (+0.26), AU: 8.93 (+0.21), VSLR: 12.00 (+0.30), NLS: 14.49 (+0.21), CCG: 7.26 (+0.01), DAC: 5.86 (-0.04), CVD: 100.39 (-0.14)
Cambrex's (CBM) CEO Steve Klosk on Q3 2014 Results -- Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 02, 1:36AM CDT
CBM: 23.28 (-0.08)
Cambrex posts 3Q profit
Automated Insights - Thu Oct 30, 8:42AM CDT
E RUTHERFORD, N.J. (AP) _ Cambrex Corp. (CBM) on Thursday reported net income of $8.8 million in its third quarter.
CBM: 23.28 (-0.08)
Cambrex (CBM) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Oct 30, 7:25AM CDT
CBM: 23.28 (-0.08)
Cambrex beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 6:27AM CDT
CBM: 23.28 (-0.08)
Cambrex Reports Third Quarter 2014 Financial Results
PR Newswire - Thu Oct 30, 6:00AM CDT
Cambrex Corporation (NYSE: CBM) reports results for the third quarter ended September 30, 2014.
CBM: 23.28 (-0.08)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 4:30PM CDT
FIS: 59.23 (-0.07), HST: 22.70 (-0.03), CRR: 48.10 (+0.02), CAH: 80.33 (-0.33), AMT: 99.76 (-0.19), ACIW: 19.30 (+0.42), GTI: 4.18 (-0.02), IDA: 61.07 (-0.11), CRCM: 8.88 (-0.09), CVRR: 23.06 (-0.06), BGCP: 8.59 (+0.01), GOV: 23.03 (-0.05), DFT: 31.26 (-0.27), APO: 22.91 (+0.28), FIG: 7.62 (+0.01), AMAG: 34.97 (+0.73), HAR: 106.24 (-0.33), AVP: 9.99 (-0.27), EXLS: 28.79 (+0.14), INGR: 80.52 (+0.68), ALU: 3.08 (+0.03), INCY: 68.81 (-2.40), COP: 71.15 (+0.80), GEL: 47.08 (+0.08), COR: 38.41 (unch), GTLS: 43.16 (-0.84), BWA: 55.06 (-0.24), CARB: 11.65 (+0.17), GLOP: 23.36 (-0.30), IDCC: 50.28 (+0.61), HEES: 36.95 (-0.23), BCO: 21.54 (+0.29), DST: 100.03 (+0.68), EPD: 37.50 (+0.23), ABMD: 33.07 (-0.41), CEVA: 16.93 (+1.05), BLL: 64.66 (-0.50), GBX: 63.15 (-0.35), GNC: 43.58 (-0.08), CVI: 47.49 (+0.39), ACOR: 33.27 (-0.46), I: 17.81 (-0.02), FCN: 41.21 (+0.12), CRNT: 1.13 (-0.02), DHX: 11.25 (-0.06), BG: 88.90 (+0.15), CME: 85.04 (-0.10), FCH: 10.58 (-0.04), ALLE: 52.40 (+0.28), AUDC: 4.58 (-0.04), APD: 135.48 (-0.05), DBD: 35.35 (+0.17), HGG: 6.18 (+0.02), CBM: 23.28 (-0.08), CNSL: 27.18 (+0.08), ATK: 110.90 (-0.24), ANR: 2.47 (+0.05), CI: 101.89 (-0.82), ABC: 88.63 (-0.45), GG: 19.80 (+0.55)
Cambrex to Announce Third Quarter 2014 Financial Results on October 30, 2014
PR Newswire - Tue Oct 28, 2:03PM CDT
Cambrex Corporation (NYSE: CBM) announced that third quarter 2014 financial results will be released on Thursday, October 30, 2014 before the market opens.
CBM: 23.28 (-0.08)
Shares of CBM Down 10.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Oct 22, 11:22AM CDT
SmarTrend identified a Downtrend for Cambrex (NYSE:CBM) on September 23rd, 2014 at $19.89. In approximately 4 weeks, Cambrex has returned 10.61% as of today's recent price of $17.78.
CBM: 23.28 (-0.08)
Halozyme's PEGPH20 Receives FDA Orphan Drug Designation - Analyst Blog
Kanchan Khanna - Zacks Investment Research - Tue Oct 07, 4:40PM CDT
Halozyme Therapeutics, Inc. (HALO) has gained orphan drug status for PEGPH20 for the treatment of pancreatic cancer.
HALO: 8.48 (-0.26), CBM: 23.28 (-0.08), VVUS: 3.29 (+0.03), LGND: 58.13 (+0.17)
Pluristem Therapeutics, Inc. (PSTI) in Focus: Stock Up 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 7:44AM CDT
Pluristem Therapeutics, Inc. (PSTI) was a big mover last session, as the company saw its shares rise over 7% on the day
CBM: 23.28 (-0.08), PSTI: 2.70 (+0.01), ONTY: 1.63 (-0.05)
Alexion Pharmaceuticals (ALXN) in Focus: Stock Rises 6.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 7:44AM CDT
Alexion Pharmaceuticals, Inc. (ALXN) was a big mover last session, as the company saw its shares rise 6% on the day
CBM: 23.28 (-0.08), ALXN: 188.35 (-5.24), ONTY: 1.63 (-0.05)
Weakness Seen in Vital Therapies (VTL): Stock Falls 6.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 7:42AM CDT
Vital Therapies (VTL) fell over 6% in the last trading session amid huge volumes, continuing its recent trend, as the stock is down over 26% in the past one-month time frame.
CBM: 23.28 (-0.08), VTL: 18.00 (+0.18), PDLI: 7.72 (-0.17)
Managing the API Life Cycle: Cambrex Innovation, Process and Cost Improvement, Live Webinar Hosted by Xtalks
Marketwire - Mon Oct 06, 6:05AM CDT
This webinar will examine how pharmaceutical companies can manage their Active Pharmaceutical Ingredient (API) life cycle through innovation, process and cost improvements in order to meet clinical and commercial objectives and to help move their products quickly to market. Join this webinar to learn more on Thursday, October 16, 2014 at 11am EDT (NA) / 4pm BST (UK GMT+1).
CBM: 23.28 (-0.08)
CorMedix Files IND Application for Neutrolin in the US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 4:10PM CDT
CorMedix Inc. (CRMD) announced that it has filed an Investigational New Drug (IND) application to the FDA for Neutrolin.
CRMD: 1.56 (+0.16), CBM: 23.28 (-0.08), GILD: 100.57 (-3.63), RGDO: 0.85 (-0.02)
CBM Recent Posts: http://investorshangout.com/Cambrex-Corp-CBM-50451/
CBM Cambrex Corp Recent Headline News
Cambrex Shares Up 20.2% Since SmarTrend's Buy Recommendation (CBM)
Comtex SmarTrend(R) - Wed Nov 12, 9:19AM CST
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on October 28th, 2014 at $19.26. In approximately 2 weeks, Cambrex has returned 20.18% as of today's recent price of $23.14.
CBM: 23.28 (-0.08)
Can the Rally in Cambrex (CBM) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:34AM CST
Can the Rally in Cambrex (CBM) Shares Continue?
CBM: 23.28 (-0.08)
NYSE stocks posting largest percentage increases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
DHX: 11.25 (-0.06), HLF: 37.37 (-0.48), CBM: 23.28 (-0.08), ESI: 10.25 (+0.23), JMP: 7.51 (-0.04), THR: 25.45 (+0.26), AU: 8.93 (+0.21), VSLR: 12.00 (+0.30), NLS: 14.49 (+0.21), CCG: 7.26 (+0.01), DAC: 5.86 (-0.04), CVD: 100.39 (-0.14)
Cambrex's (CBM) CEO Steve Klosk on Q3 2014 Results -- Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 02, 1:36AM CDT
CBM: 23.28 (-0.08)
Cambrex posts 3Q profit
Automated Insights - Thu Oct 30, 8:42AM CDT
E RUTHERFORD, N.J. (AP) _ Cambrex Corp. (CBM) on Thursday reported net income of $8.8 million in its third quarter.
CBM: 23.28 (-0.08)
Cambrex (CBM) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Oct 30, 7:25AM CDT
CBM: 23.28 (-0.08)
Cambrex beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 6:27AM CDT
CBM: 23.28 (-0.08)
Cambrex Reports Third Quarter 2014 Financial Results
PR Newswire - Thu Oct 30, 6:00AM CDT
Cambrex Corporation (NYSE: CBM) reports results for the third quarter ended September 30, 2014.
CBM: 23.28 (-0.08)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 4:30PM CDT
FIS: 59.23 (-0.07), HST: 22.70 (-0.03), CRR: 48.10 (+0.02), CAH: 80.33 (-0.33), AMT: 99.76 (-0.19), ACIW: 19.30 (+0.42), GTI: 4.18 (-0.02), IDA: 61.07 (-0.11), CRCM: 8.88 (-0.09), CVRR: 23.06 (-0.06), BGCP: 8.59 (+0.01), GOV: 23.03 (-0.05), DFT: 31.26 (-0.27), APO: 22.91 (+0.28), FIG: 7.62 (+0.01), AMAG: 34.97 (+0.73), HAR: 106.24 (-0.33), AVP: 9.99 (-0.27), EXLS: 28.79 (+0.14), INGR: 80.52 (+0.68), ALU: 3.08 (+0.03), INCY: 68.81 (-2.40), COP: 71.15 (+0.80), GEL: 47.08 (+0.08), COR: 38.41 (unch), GTLS: 43.16 (-0.84), BWA: 55.06 (-0.24), CARB: 11.65 (+0.17), GLOP: 23.36 (-0.30), IDCC: 50.28 (+0.61), HEES: 36.95 (-0.23), BCO: 21.54 (+0.29), DST: 100.03 (+0.68), EPD: 37.50 (+0.23), ABMD: 33.07 (-0.41), CEVA: 16.93 (+1.05), BLL: 64.66 (-0.50), GBX: 63.15 (-0.35), GNC: 43.58 (-0.08), CVI: 47.49 (+0.39), ACOR: 33.27 (-0.46), I: 17.81 (-0.02), FCN: 41.21 (+0.12), CRNT: 1.13 (-0.02), DHX: 11.25 (-0.06), BG: 88.90 (+0.15), CME: 85.04 (-0.10), FCH: 10.58 (-0.04), ALLE: 52.40 (+0.28), AUDC: 4.58 (-0.04), APD: 135.48 (-0.05), DBD: 35.35 (+0.17), HGG: 6.18 (+0.02), CBM: 23.28 (-0.08), CNSL: 27.18 (+0.08), ATK: 110.90 (-0.24), ANR: 2.47 (+0.05), CI: 101.89 (-0.82), ABC: 88.63 (-0.45), GG: 19.80 (+0.55)
Cambrex to Announce Third Quarter 2014 Financial Results on October 30, 2014
PR Newswire - Tue Oct 28, 2:03PM CDT
Cambrex Corporation (NYSE: CBM) announced that third quarter 2014 financial results will be released on Thursday, October 30, 2014 before the market opens.
CBM: 23.28 (-0.08)
Shares of CBM Down 10.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Oct 22, 11:22AM CDT
SmarTrend identified a Downtrend for Cambrex (NYSE:CBM) on September 23rd, 2014 at $19.89. In approximately 4 weeks, Cambrex has returned 10.61% as of today's recent price of $17.78.
CBM: 23.28 (-0.08)
Halozyme's PEGPH20 Receives FDA Orphan Drug Designation - Analyst Blog
Kanchan Khanna - Zacks Investment Research - Tue Oct 07, 4:40PM CDT
Halozyme Therapeutics, Inc. (HALO) has gained orphan drug status for PEGPH20 for the treatment of pancreatic cancer.
HALO: 8.48 (-0.26), CBM: 23.28 (-0.08), VVUS: 3.29 (+0.03), LGND: 58.13 (+0.17)
Pluristem Therapeutics, Inc. (PSTI) in Focus: Stock Up 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 7:44AM CDT
Pluristem Therapeutics, Inc. (PSTI) was a big mover last session, as the company saw its shares rise over 7% on the day
CBM: 23.28 (-0.08), PSTI: 2.70 (+0.01), ONTY: 1.63 (-0.05)
Alexion Pharmaceuticals (ALXN) in Focus: Stock Rises 6.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 7:44AM CDT
Alexion Pharmaceuticals, Inc. (ALXN) was a big mover last session, as the company saw its shares rise 6% on the day
CBM: 23.28 (-0.08), ALXN: 188.35 (-5.24), ONTY: 1.63 (-0.05)
Weakness Seen in Vital Therapies (VTL): Stock Falls 6.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 7:42AM CDT
Vital Therapies (VTL) fell over 6% in the last trading session amid huge volumes, continuing its recent trend, as the stock is down over 26% in the past one-month time frame.
CBM: 23.28 (-0.08), VTL: 18.00 (+0.18), PDLI: 7.72 (-0.17)
Managing the API Life Cycle: Cambrex Innovation, Process and Cost Improvement, Live Webinar Hosted by Xtalks
Marketwire - Mon Oct 06, 6:05AM CDT
This webinar will examine how pharmaceutical companies can manage their Active Pharmaceutical Ingredient (API) life cycle through innovation, process and cost improvements in order to meet clinical and commercial objectives and to help move their products quickly to market. Join this webinar to learn more on Thursday, October 16, 2014 at 11am EDT (NA) / 4pm BST (UK GMT+1).
CBM: 23.28 (-0.08)
CorMedix Files IND Application for Neutrolin in the US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 4:10PM CDT
CorMedix Inc. (CRMD) announced that it has filed an Investigational New Drug (IND) application to the FDA for Neutrolin.
CRMD: 1.56 (+0.16), CBM: 23.28 (-0.08), GILD: 100.57 (-3.63), RGDO: 0.85 (-0.02)
